#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
preLekára.sk / Journals / Nuclear Medicine / 2020 - 3

Role of scintigraphic procedures in patients with heart failure and preserved ejection fraction

Česká verzia

Authors: Otto Lang
Authors place of work: Oddělení nukleární medicíny, Oblastní nemocnice Příbram, a. s. ;  Oddělení nukleární medicíny, PMCD s. r. o., Praha 6, ČR ;  Klinika nukleární medicíny, 3. LF UK a FN Královské Vinohrady, Praha 10
Published in the journal: NuklMed 2020;9:49-58
Category: Review Article

Summary

Introduction: Heart failure with preserved ejection fraction (HFpEF) is responsible for approximately half of all heart failure cases and its frequency is still growing. Pathophysiological changes are very complex. They include maladaptation, remodeling and hypertrophy, apoptosis, death and regeneration of myocardial muscle cells. Functional impairment can be of different origin, there is usually a combination of different causes. Ischemia, metabolic disorders, sympathetic system impairment and some others (inflammation, restrictive cardiomypathy) are the most significant.

Method: Nuclear medicine procedures are based on pathophysiological processes so they can play an important role in the diagnosis of this type of HF. Radionuclide ventriculography (RNV), myocardial perfusion imaging (MPI), imaging of glucose metabolism (FDG), autonomous neuropathy and cardiac sarcoidosis and amyloidosis are the routinely used procedures.

Results: RNV serves mainly to detect changes of left ventricular function during physical stress, MPI to detect myocardial ischemia even when coronary aterosclerosis in not present, FDG is used to detect myocardial viability in patients after myocardial infarction. Autonomous neuropathy is dected as a sympathetic dysfunction. Scintigrahic procedures play a significant role in resctritive cardiomyopathies if the cause is sarcoidosis or amyloidosis. Scintigraphy of amyloidosis, in some circumstances, can even replace endomyocardial biopsy.

Conclusion: Scintigraphic procedures can play a significant role in the diagnosis of HFpEF. But they must be well indicated, profesionally performed and wisely interpreted.

Keywords:

PET – scintigraphy – HFpEF – SPECT

Zdroje

  1. Hajouli S, Ludhwani D. Heart Failure And Ejection Fraction. [Updated 2020 Jun 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK553115/

  2. Oktay AA, Shah SJ. Diagnosis and management of heart failure with preserved ejection fraction: 10 key lessons. Curr Cardiol Rev. 2015;11(1):42-52. doi:10.2174/1573403x09666131117131217

  3. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006;355:251-9, DOI: 10.1056/NEJMoa052256

  4. Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011;13:18-28

  5. Lam CS, Carson PE, Anand IS, et al. Sex differences in clinical characteristics and outcomes in elderly patients with heart failureand preserved ejection fraction: the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail 2012;5:571-578

  6. Shah SJ. Precision Medicine for Heart Failure with Preserved Ejection Fraction: An Overview. J Cardiovasc Transl Res. 2017 June;10:233–244. doi:10.1007/s12265-017-9756-y.

  7. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115:79–96

  8. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014; 11(9):507–515.

  9. Sanderson JE. HFNEF, HFpEF, HF-PEF, or DHF. What Is in an Acronym? JACC HF 2014;2:93-94

  10. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009;22:107-133

  11. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018

  12. Paulus WJ, Tschope C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Association of the European Society of Cardiology. Eur Heart J 2007;28:2539–2550

  13. Dunlay SM, Roger VL, Weston SA, Jiang R, Redfield MM. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail 2012;5:720–726

  14. Tanai E, Frantz S. Pathophysiology of Heart Failure. Compr Physiol. 2015;6:187-214 Published 2015 Dec 15. doi:10.1002/cphy.c140055

  15. van Heerebeek L. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J 2016;24:227–236

  16. Carsten T, et al. Latent ischaemia as a trigger for a circulus vitiosus of inflammation, fibrosis, and stiffness in HFPEF. European Journal of Heart Failure (2015);17:1210–1212

  17. Steinberg BA, Zhao X, Heidenreich PA, et al. Trends in patients hospitalized with heart failure and preserved left ventricular ejection fraction: prevalence, therapies, and outcomes. Circulation 2012;126:65-75

  18. Lang O. Scintigrafie u diabetické kardiomyopatie. NuklMed 2013;4:62-67

  19. van Empel V, Brunner-La Rocca HP. Inflammation in HFpEF: Key or circumstantial?. Int J Cardiol. 2015;189:259-263 doi:10.1016/j.ijcard.2015.04.110

  20. Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation, J. Am. Coll. Cardiol. 2013;62:263–271

  21. Shah SJ, Wasserstrom JA. Increased arterial wave reflection magnitude: a novel form of stage B heart failure? J Am Coll Cardiol. 2012; 60:2178–2181

  22. Farrell MB, Galt JR, Georgoulias P et al. SNMMI Procedure Standard/EANM Guideline for Gated Equilibrium Radionuclide Angiography. J Nucl Med Technol. 2020 Jun;48:126-135 doi: 10.2967/jnmt.120.246405.

  23. Vered A, Battler A, Segal P, et al. Exercise-induced left ventricular dysfunction in young men with asymptomatic diabetes mellitus (diabetic cardiomyopathy). Am J Cardiol 1984;54:633-637

  24. Strauss HW, Miller DD, Wittry MD et al. Procedure guideline for myocardial perfusion imaging 3.3. J Nucl Med Technol. 2008 Sep;36:155-161 doi: 10.2967/jnmt.108.056465.

  25. Dorbala S, Di Carli MF, Delbeke D et al. SNMMI/ASNC/SCCT guideline for cardiac SPECT/CT and PET/CT 1.0. J Nucl Med. 2013 Aug;54:1485-1507 doi: 10.2967/jnumed.112.105155.

  26. Tschope C, Post H. Latent ischaemia as a trigger for a circulus vitiosus of inflammation, fibrosis, and stiffness in HFPEF. European Journal of Heart Failure 2015;17:1210–1212 doi:10.1002/ejhf.439

  27. Xu M, Yan L, Xu J et al. Predictors and prognosis for incident in-hospital heart failure in patients with preserved ejection fraction after first acute myocardial infarction. An observational study. Medicine 2018;97:24(e11093). doi: 10.1097/MD.0000000000011093

  28. Jones RH, Velazquez EJ, Michler RE et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N. Engl. J. Med. 2009 Apr 23;360:1705-1717

  29. Wackers FJT, Chyun DA, Young LH, et al. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. Diabetes Care 2007;30:2892-2898

  30. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights from the NHLBISponsored Women‘s Ischemia Syndrome Evaluation (WISE) Study: Part II: gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006;47:S21-S29

  31. Dorbala S, Vangala D, Bruyere J Jr, et al. Coronary microvascular dysfunction is related to abnormalities in myocardial structure and function in cardiac amyloidosis. JACC Heart Fail. 2014;2:358-367 doi:10.1016/j.jchf.2014.03.009

  32. Bashir A, Gropler RJ. Translation of Myocardial Metabolic Imaging Concepts into the Clinics. Cardiol Clin 2009;27: 291-319

  33. Kaye DM, Lambert GW, Lefkovits J et al. Neurochemical evidence of cardiac sympathetic activation and increased central nervous system norepinephrine turnover in severe congestive heart failure. J Am Coll Cardiol. 1994;23:570–578

  34. Voulgari C, Papadogiannis D, Tentolouris N. Diabetic cardiomyopathy: from the pathophysiology of the cardiac myocytes to current diagnosis and management strategies. Vasc Health Risk Manag 2010;6:883-903

  35. Aikawa T, Naya M, Obara M et al. Impaired Myocardial Sympathetic Innervation Is Associated with Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction: 11C-Hydroxyephedrine PET Study. J Nucl Med 2017;58:784–790 DOI: 10.2967/jnumed.116.178558

  36. Kiuchi S, Hisatake S, Kabuki T et al. Effect of Switching from Cilnidipine to Azelnidipine on Cardiac Sympathetic Nerve Function in Patients with Heart Failure Preserved Ejection Fraction. Int Heart J 2018;59:120-125

  37. Lee WW. Recent Advances in Nuclear Cardiology. Nucl Med Mol Imaging (2016) 50:196–206 DOI 10.1007/s13139-016-0433-x

  38. Yazaki Y, Isobe M, Hiroe M et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol. 2001;88:1006–1010

  39. BirnieDH, SauerWH, Bogun F et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–1323

  40. Lu Y, Grant C, Xie K et al. Suppres-sion of myocardial 18F-FDG uptake through prolonged high-fat, high-protein, and very-low-carbohydrate diet before FDG-PET/CT for eval-uation of patients with suspected cardiac sar-coidosis. Clin Nucl Med 2017; 42: 88-94

  41. Slart RHJA, Glaudemans AWJM, Lancellotti P, et al. A joint procedural position statement on imaging in cardiac sarcoidosis: from the Cardiovascular and Inflammation & Infection Committees of the European Association of Nuclear Medicine, the European Association of Cardiovascular Imaging, and the American Society of Nuclear Cardiology. J Nucl Cardiol. 2018;25:298-319 doi:10.1007/s12350-017-1043-4

  42. Keijsers RGM, Grutters JC. In Which Patients with Sarcoidosis Is FDG PET/CT Indicated?. J Clin Med. 2020;9:890 Published 2020 Mar 24. doi:10.3390/jcm9030890

  43. Youssef, G, Leung, E, Mylonas, I et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: A systematic review and metaanalysis including the Ontario experience. J. Nucl. Med. 2012;53:241–248

  44. Tetikkurt C, Sayman H, Dedeoglu SE, Kubat B, Tetikkurt S. Simultaneous use of FDG-18 and 68Ga-citrate PET/CT for the differential diagnosis of sarcoidosis and malignant disease. Monaldi Arch Chest Dis. 2020;90:10.4081/monaldi.2020.1320. Published 2020 Jul 29. doi:10.4081/monaldi.2020.1320

  45. Benson MD, Buxbaum JN, Eisenberg DS et al. Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee, Amyloid 2018;25:215–219

  46. Papathanasiou M, Carpinteiro A, Rischpler C et al. Diagnosing cardiac amyloidosis in every-day practice: A practical guide for the cardiologist. IJC Heart & Vasculature 28 (2020) 100519

  47. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis, Lancet 2016;387:2641–2654

  48. Gillmore JD, Maurer MS, Falk RH et al., Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404–2412

  49. Kula RW, Engel WK, Line BR. Scanning for soft-tissue amyloid. Lancet. 1977;1:92–93

  50. Perugini E, Guidalotti PL, Salvi F et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-1084. doi:10.1016/j.jacc.2005.05.073

  51. Fathala A. Incidentally detected cardiac amyloidosis on 99mTc-MDP bone scintigraphy. Radiol Case Rep. 2020;15:705-708. Published 2020 Apr 7. doi:10.1016/j.radcr.2020.03.010

  52. Rapezzi C, Quarta CC, Guidalotti PL et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging 2011;38:470–478

  53. Bokhari S, Shahzad R, Castaño A et al. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014;21:175–184 doi:10.1007/s12350-013-9803-2.

  54. Bokhari S, Castaño A, Pozniakoff T et al. 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ Cardiovasc Imaging 2013;6:195–201

  55. Noordzij W, Glaudemans AW, Rheenen RW et al. (123)I-Labelled metaiodobenzylguanidine for the evaluation of cardiac sympathetic denervation in early stage amyloidosis. Eur J Nucl Med Mol Imaging 2012;39:1609–1617

  56. Fink HA, Hemmy LS, Linskens EJ, et al. Diagnosis and Treatment of Clinical Alzheimer’s-Type Dementia: A Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); April 2020.

  57. Antoni G, Lubberink M, Estrada S, Axelsson J, Carlson K, Lindsjö L, et al. In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET. J Nucl Med. 2012;54:213–220.

  58. Ehman EC, El-Sady MS, Kijewski MF, et al. Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET/CT. J Nucl Med. 2019;60:1234-1239 doi:10.2967/jnumed.118.221770

Štítky
Nuclear medicine Radiodiagnostics Radiotherapy
Článek The value of FDG PET/CT in the thromboembolic disease: review of the literature
Článek What can you see on the image?
Článok vyšiel v časopise

Nuclear Medicine

Číslo 3
2020 Číslo 3
Najčítanejšie v tomto čísle
Prihlásenie
Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa

#ADS_BOTTOM_SCRIPTS#